Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson

Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson


Andy Jassy, chief executive officer of Amazon.Com Inc., during the GeekWire Summit in Seattle, Washington, U.S., on Tuesday, Oct. 5, 2021.

David Ryder | Bloomberg | Getty Images

Amazon is developing cancer vaccines in collaboration with the Fred Hutchinson Cancer Research Center, and it recently launched an FDA-approved clinical trial.

Amazon and Fred Hutchinson are looking to recruit 20 participants over the age of 18 for the early stage, or phase 1, trial, according to a filing on clinicaltrials.gov, a database of clinical trials run by the National Library of Medicine. The goal is to develop “personalized vaccines” that can treat breast cancer and melanoma, a form of skin cancer, the filing states.

Fred Hutchinson is listed as a sponsor of the study, while Amazon is listed as a collaborator, according to the filing. News of the partnership was first reported by Business Insider. The study was first posted last October, and it began June 9. It’s expected to be complete by Nov. 1 of 2023.

Fred Hutch and Amazon confirmed the partnership. An Amazon spokesperson said it’s being led by Fred Hutch.

“Amazon is contributing scientific and machine learning expertise to a partnership with Fred Hutch to explore the development of a personalized treatment for certain forms of cancer,” the spokesperson told CNBC in a statement. “It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial, and it’s unclear whether it will be successful. This will be a long, multi-year process — should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.”

Amazon has deepened its presence in the health-care industry in recent years. The company in 2020 launched an online pharmacy, it has ramped up its telehealth service, called Amazon Care, and it has sought to develop at-home medical diagnostics.

A secretive research and development group inside Amazon, known as Grand Challenge, initially oversaw the cancer vaccine effort, according to Business Insider, which cited people familiar with the matter. It’s now under the purview of a cancer research team reporting to Amazon’s vice president of devices, Robert Williams, Business Insider reported.

WATCH: Andy Jassy’s priority is to chart a next generation path for growth, says Madron’s McIlwain



Source

AMD’s Lisa Su says AI isn’t replacing people, but is changing who gets hired
Technology

AMD’s Lisa Su says AI isn’t replacing people, but is changing who gets hired

Advanced Micro Devices CEO Lisa Su said Tuesday that artificial intelligence has not slowed the pace of hiring at her company, but the job candidates who have truly embraced the technology have become a priority. “I would say that we’re actually not hiring fewer people,” Su told CNBC’s Jon Fortt on Tuesday from the CES […]

Read More
Meta delays Ray-Ban Display glasses global rollout due to inventory limits, U.S. demand
Technology

Meta delays Ray-Ban Display glasses global rollout due to inventory limits, U.S. demand

Meta CEO Mark Zuckerberg wears the Meta Ray-Ban Display glasses, as he delivers a speech presenting the new line of smart glasses, during the Meta Connect event at the company’s headquarters in Menlo Park, California, U.S., Sept. 17, 2025. Carlos Barria | Reuters Meta Platforms said Tuesday that it’s delaying the international expansion of its […]

Read More
Maduro pleads not guilty, Nvidia’s robotaxi play, JPMorgan’s ‘secret sauce’ and more in Morning Squawk
Technology

Maduro pleads not guilty, Nvidia’s robotaxi play, JPMorgan’s ‘secret sauce’ and more in Morning Squawk

This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. We’re not even a week into the new year and I’ve already started telling myself that my resolution to read more can include reviewing drafts of this newsletter. Stock futures are little changed this morning. The market is coming off […]

Read More